What smart money is saying about Arvinas
1 fund in our archive has pitched Arvinas — most recently 1 Main Capital in March 2025.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- 1 Main CapitalMarch 2025
Arvinas (ARVN) is a clinical-stage biotech company with significant cash reserves and collaboration agreements, but its market value has plummeted over 90% due to disappointing trial results.
Read the full thesis
Read every full thesis on Arvinas
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→